The group expects to raise nearly $170m.
ApexOnco Front Page
Recent articles
Can the company add a Car-T string to its stem cell transplant bow?
BGB-16673 and BGB-43395 will soon both be in phase 3 trials, BeiGene reveals.
Another SERD catalyst and the son of Darzalex take centre stage.
Tough equity markets as well as competitor developments prompt a narrowed focus.
Giredestrant will soon become the first oral SERD to yield first-line data.
The company hits an FDA-mandated enrolment target, but only in follicular lymphoma.
The company is starting a phase 3 trial of sacituzumab tirumotecan in first-line TNBC.
